CYDY CytoDyn Inc

  1. Stocks
  2. Healthcare
  3. OTC: CYDY

Price (delayed)

$0.15

Market cap

$94.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$124.42M

Highlights
The EPS is up by 18% since the previous quarter and by 10% year-on-year
CYDY's quick ratio has soared by 100% QoQ but it is down by 31% YoY
CytoDyn's net income has decreased by 24% YoY but it has increased by 8% QoQ
The debt has surged by 64% since the previous quarter
CytoDyn's equity has decreased by 33% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: CMRX UTHR NNVC

Key stats

What are the main financial stats of CYDY
Market
Shares outstanding
632.59M
Market cap
$94.89M
Enterprise value
$124.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$150.29M
EBITDA
-$150.29M
Free cash flow
-$117,695
Per share
EPS
-$0.27
Free cash flow per share
$0
Book value per share
-$0.03
Revenue per share
$0
TBVPS
$0.22
Balance sheet
Total assets
$132.08M
Total liabilities
$153.1M
Debt
$63.47M
Equity
-$21.02M
Working capital
-$22.97M
Liquidity
Debt to equity
-3.02
Current ratio
0.85
Quick ratio
0.22
Net debt/EBITDA
-0.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-128.1%
Return on equity
N/A
Return on invested capital
-856.9%
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYDY stock price

How has the CytoDyn stock price performed over time
Intraday
0%
1 week
1.35%
1 month
-8.2%
1 year
-50.66%
YTD
-23.08%
QTD
-8.14%

Financial performance

How have CytoDyn's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.6M
Net income
-$154.67M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 40% year-on-year but it is up by 3.8% since the previous quarter
CytoDyn's net income has decreased by 24% YoY but it has increased by 8% QoQ

Growth

What is CytoDyn's growth rate over time

Valuation

What is CytoDyn stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% since the previous quarter and by 10% year-on-year
CytoDyn's equity has decreased by 33% QoQ

Efficiency

How efficient is CytoDyn business performance
The company's return on assets has surged by 68% YoY and by 23% QoQ
CYDY's return on invested capital is up by 26% since the previous quarter

Dividends

What is CYDY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYDY.

Financial health

How did CytoDyn financials performed over time
CYDY's total assets is 14% smaller than its total liabilities
The company's total liabilities has surged by 189% YoY and by 18% QoQ
CYDY's total assets has surged by 161% year-on-year and by 16% since the previous quarter
The debt has surged by 64% since the previous quarter
CytoDyn's debt to equity has surged by 51% YoY but it has decreased by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.